SecBot SecBot
8-K ·Filed Feb 26, 2026

VTVT

vTv Therapeutics Inc.
NEUTRAL
Impact 4/10
Horizonmonths Processed8mo ago SEC0001641489-26-000005
8-K context-dependent: Items 7.01
Actionable Insight • Neutral

Monitor for topline Phase 3 CATT1 data in 2H 2026, which will be a critical catalyst for the stock. The current cash position provides sufficient runway to reach this milestone.

DirectionNeutral
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$39.32
T+0 close · Feb 26, 2026 · via day close
Latest settled
−9.72%
T+60 · $35.50
Vs SPY
−17.47%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Feb 26 $39.32entry
  2. T+1 · 9mo ago −2.95%α −2.50% · $38.16
  3. T+5 · 9mo ago −5.34%α −4.21% · $37.22
  4. T+20 · 8mo ago −3.87%α +2.54% · $37.80
  5. T+60 · 6mo ago −9.72%α −17.47% · $35.50
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

vTv Therapeutics released an investor presentation disclosing that its lead asset, Cadisegliatin, is in Phase 3 development for type 1 diabetes, with topline data expected in the second half of 2026. The company highlighted a strong balance sheet with $118.5 million in cash, providing runway past the data readout. No new financial guidance or clinical results were provided.

Key Facts

  • Cadisegliatin is in Phase 3 development for type 1 diabetes with topline CATT1 data targeted for 2H 2026
  • Company has $98.5M cash as of 9/30/2025 plus $20.0M received on 2/2/2026, totaling $118.5M
  • Cadisegliatin has FDA Breakthrough Therapy Designation for treatment of T1D
  • Presentation contains forward-looking statements about future operations and financial performance

Financial Impact

$118.5 million cash runway through 2H 2026

cashbalance sheet strengthrunway

Risk Factors

  • Clinical trial failure risk for Cadisegliatin
  • Dependence on successful Phase 3 results for company valuation
  • Dilution risk if additional funding is needed beyond current runway

Market Snapshot

Exchange
Nasdaq

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001641489-26-000005
Document: vtvt-20260226.htm0001641489-26-000005
Document: 0001641489-26-000005-index-headers.html0001641489-26-000005
Document: 0001641489-26-000005-index.html0001641489-26-000005
Document: 0001641489-26-000005.txt0001641489-26-000005

US Market Status

Market Closed · Opens in 5h 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Feb 26, 2026